Saccade responses to dopamine in human MPTP‐induced parkinsonism

Depletion of dopamine content in the substantia nigra resulting from 1‐methyl‐4‐phenyl‐1,2,5,6‐tetrahydropyridine (MPTP) toxicity produces parkinsonism. Management of 3 patients with MPTP‐induced parkinsonism required drug holidays during which there was a state of dopamine depletion followed by dopamine replacement. We used this opportunity to study the effect of the selective loss of pars compacta dopaminergic cells on vertical and horizontal saccade (fast) eye movements. During the drug holidays, visually guided saccades were hypometric and had long latencies but retained a normal saccade velocity–amplitude relationship. Dopamine agonists or precursors improved the accuracy and reaction times of saccades in all directions, but not their velocity. Two of the three patients also had intermittent blepharospasm during dopamine depletion. During the episodes of blepharospasm, saccade responses became slow eye movements. MPTP causes a dopaminergic‐responsive disorder of saccade initiation that is similar to idiopathic parkinsonism. The inhibition of voluntary eyelid opening during MPTP‐induced blepharospasm further increases this impairment of fast eye movements and altered saccade velocity, presumably via the pars reticulata of the substantia nigra.

[1]  R. Tomlinson,et al.  Ocular motor deficits in Parkinson's disease. III. Coordination of eye and head movements. , 1988, Brain : a journal of neurology.

[2]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[3]  R. Wurtz,et al.  Modification of saccadic eye movements by GABA-related substances. I. Effect of muscimol and bicuculline in monkey superior colliculus. , 1985, Journal of neurophysiology.

[4]  R. Wurtz,et al.  Modification of saccadic eye movements by GABA-related substances. II. Effects of muscimol in monkey substantia nigra pars reticulata. , 1985, Journal of neurophysiology.

[5]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[6]  J. Hotson,et al.  Vertical saccades in Huntington's disease and non-degenerative choreoathetoid disorders , 1984 .

[7]  R. Tomlinson,et al.  Ocular motor deficits in Parkinson's disease. II. Control of the saccadic and smooth pursuit systems. , 1983, Brain : a journal of neurology.

[8]  C. Markham,et al.  Evaluating the evaluations , 1983, Neurology.

[9]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Wurtz,et al.  Visual and oculomotor functions of monkey substantia nigra pars reticulata. IV. Relation of substantia nigra to superior colliculus. , 1983, Journal of neurophysiology.

[11]  R. Wurtz,et al.  Visual and oculomotor functions of monkey substantia nigra pars reticulata. I. Relation of visual and auditory responses to saccades. , 1983, Journal of neurophysiology.

[12]  J. Jankovic,et al.  Blepharospasm and orofacial‐cervical dystonia: Clinical and pharmacological findings in 100 patients , 1983, Annals of neurology.

[13]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[14]  A. Fuchs,et al.  Fatigue resistance of human extraocular muscles. , 1983, Journal of neurophysiology.

[15]  C. Marsden,et al.  Reversible supranuclear ophthalmoplegia associated with Parkinsonism. , 1980, Journal of neurology, neurosurgery, and psychiatry.

[16]  M. Kupersmith,et al.  Evaluation of Parkinson's disease. , 1980, Advances in biochemical psychopharmacology.

[17]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[18]  A. Hakim,et al.  Dementia in Parkinson disease , 1979, Neurology.

[19]  H. Shibasaki,et al.  Oculomotor abnormalities in Parkinson's disease. , 1979, Archives of neurology.

[20]  J. Sharpe,et al.  Effect of aging on horizontal smooth pursuit. , 1978, Investigative ophthalmology & visual science.

[21]  Lawrence Stark,et al.  Overlapping saccades and glissades are produced by fatigue in the saccadic eye movement system , 1975, Experimental Neurology.

[22]  H D Crane,et al.  Accurate two-dimensional eye tracker using first and fourth Purkinje images. , 1973, Journal of the Optical Society of America.

[23]  H. Bücking Determination of the Size of the Third Ventricle Following Subarachnoid Hemorrhage by Echoencephalography , 1973 .

[24]  M. B. Bender,et al.  Oculomotor function in patients with Parkinson's disease. , 1972, Journal of the neurological sciences.

[25]  G. Jones,et al.  Akinesia, hypokinesia, and bradykinesia in the oculomotor system of patients with Parkinson's disease. , 1971, Experimental neurology.

[26]  B. Cohen,et al.  Changes in saccadic eye movements of patients with Parkinson's disease before and after L-dopa. , 1969, Transactions of the American Neurological Association.

[27]  M. Dacso,et al.  A clinical disability rating for Parkinson patients. , 1968, Journal of chronic diseases.

[28]  R. Hassler,et al.  Opening and Closing of Eyes and Signs of Psychomotor Excitation resulting from Stimulation of the Putamen in Cats , 1967, Nature.

[29]  A. Starr,et al.  A disorder of rapid eye movements in Huntington's chorea. , 1967, Brain : a journal of neurology.

[30]  D. Cogan,et al.  APRAXIA OF LID OPENING. , 1965, Archives of ophthalmology.

[31]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.